Pharmaceutical Products

Description :
CAS #: 5135.89
Molecular Formula:C211H366N72O67S1
Molecular Weight:5135.89
Appearance:white powder
Purity (HPLC):≥98.00%
Tesamorelin is a?synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a?trans-3-Hexenoic acid group.

Tesamorelin (also known as Egrifta) is a?synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.

Tesamorelin is a?synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a?trans-3-Hexenoic acid group.

Tesamorelin (?also known as Egrifta) is a?synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.

Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a?condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).

Use :
Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.